Pulling SEC filings + quote and writing the call…

Taysha Gene Therapies, Inc.
Next earnings Aug 10, 2026 · consensus $-0.12 EPS, $694K rev
Last earnings +0.6% on 2026-05-06
Revenue grew 17.3% YoY; but unprofitable (net margin -1115.3%).
Taysha Gene Therapies, Inc. shows $9.77M in FY2025 revenue (+17.3% YoY), a -1115.3% net margin, and -44.1% ROE.
Sources: SEC EDGAR (CIK 0001806310, latest 10-Q filed 2026-05-06) · EODHD · as of 6/24/2026, 9:46:07 AM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | $2.50M | $15.5M | $8.33M | $9.77M |
| Gross profit | — | — | — | — | — |
| Operating income | -$173M | -$162M | -$72.4M | -$91.5M | -$110M |
| Net income | -$175M | -$166M | -$112M | -$89.3M | -$109M |
| Diluted EPS | -$4.64 | -$3.78 | -$0.96 | -$0.36 | -$0.34 |
| Net margin | — | -6635.3% | -722.1% | -1071.6% | -1115.3% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
1483 tracked peers · median
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.
Last 90 days: 0 open-market buys · 1 sale
| 2026-06-01 | Stalfort John A III Director | Award | 21.3K | |
| 2026-06-01 | Donenberg Phillip B. Director | Award | 21.3K | |
| 2026-06-01 | Long Alison S Director | Award | 21.3K | |
| 2026-06-01 | Sepp-Lorenzino Laura Director | Award | 21.3K | |
| 2026-04-10 | Nagendran Sukumar President and Head of R&D | Exercise | 19.0K @ $1.71 | $32.5K |
| 2026-04-10 | Nagendran Sukumar President and Head of R&D | Sell | 200K @ $4.46 | $892K |
| 2026-02-04 | Alam Kamran CHIEF FINANCIAL OFFICER | Sell | 1.66K @ $4.52 | $7.48K |
| 2026-01-26 | Nagendran Sukumar President and Head of R&D | Sell | 26.9K @ $4.61 | $124K |
| 2026-01-26 | Nolan Sean P. Chief Executive Officer | Sell | 41.3K @ $4.61 | $190K |
| 2026-01-23 | Nagendran Sukumar President and Head of R&D | Sell | 89.1K @ $4.75 | $423K |
| 2026-01-23 | Nolan Sean P. Chief Executive Officer | Sell | 137K @ $4.75 | $650K |